Researchers at the Icahn School of Medicine at Mount Sinai have discovered a trio of immune cells within tumor niches that are associated with immunotherapy response in hepatocellular carcinoma.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
